A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures
- Conditions
- Interventions
- First Posted Date
- 2021-10-14
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 250
- Registration Number
- NCT05077904
- Locations
- 🇺🇸
Ep0162 50626, Neptune, New Jersey, United States
🇺🇸Ep0162 50506, Phoenix, Arizona, United States
🇺🇸Ep0162 50494, Little Rock, Arkansas, United States
A Study to Test the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures
- First Posted Date
- 2021-10-13
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 300
- Registration Number
- NCT05076617
- Locations
- 🇺🇸
Ep0165 50497, Amherst, New York, United States
🇺🇸Ep0165 50298, New York, New York, United States
🇺🇸Ep0165 50490, New York, New York, United States
A Study to Test the Efficacy, Safety and Tolerability of Romosozumab Treatment in Postmenopausal Chinese Women With Osteoporosis
- First Posted Date
- 2021-10-05
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 327
- Registration Number
- NCT05067335
- Locations
- 🇨🇳
Op0002 20199, Rui'an, China
🇨🇳Op0002 20130, Beijing, China
🇨🇳Op0002 20117, Guangzhou, China
A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOG-AD)
- Conditions
- Interventions
- First Posted Date
- 2021-09-30
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 104
- Registration Number
- NCT05063162
- Locations
- 🇺🇸
Mog001 50308, Tampa, Florida, United States
🇺🇸Mog001 50297, Scottsdale, Arizona, United States
🇺🇸Mog001 50450, Palo Alto, California, United States
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Korean Study Participants With Moderate to Severe Plaque Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2021-08-25
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 47
- Registration Number
- NCT05020249
- Locations
- 🇰🇷
Ps0032 20211, Bucheon-si, Korea, Republic of
🇰🇷Ps0032 20210, Seongnam-si, Korea, Republic of
🇰🇷Ps0032 20104, Seoul, Korea, Republic of
CIDP07 Rozanolixizumab Post Trial Access Program (the PTA)
- First Posted Date
- 2021-08-20
- Last Posted Date
- 2024-01-25
- Lead Sponsor
- UCB Biopharma SRL
- Registration Number
- NCT05014724
A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus
- First Posted Date
- 2021-07-26
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 760
- Registration Number
- NCT04976322
- Locations
- 🇺🇸
Sl0046 50273, Las Vegas, Nevada, United States
🇵🇱Sl0046 40090, Poznan, Poland
🇨🇳Sl0046 20113, Taichung City, Taiwan
A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
- First Posted Date
- 2021-05-25
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 658
- Registration Number
- NCT04901195
- Locations
- 🇺🇸
Hs0005 50105, Saint Louis, Missouri, United States
🇺🇸Hs0005 50194, Omaha, Nebraska, United States
🇺🇸Hs0005 50140, Birmingham, Alabama, United States
A Study to Evaluate the Pharmacokinetics and Safety of Brivaracetam in Healthy Chinese Subjects
- First Posted Date
- 2021-05-12
- Last Posted Date
- 2023-03-13
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 12
- Registration Number
- NCT04882540
- Locations
- 🇨🇳
Ep0101 101, Shanghai, Shanghai, China
A Study to Test the Efficacy, Safety, and Pharmacokinetics of Rozanolixizumab in Adult Study Participants With Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis
- Conditions
- Interventions
- First Posted Date
- 2021-05-06
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 12
- Registration Number
- NCT04875975
- Locations
- 🇺🇸
Aie001 50342, Jacksonville, Florida, United States
🇺🇸Aie001 50298, New York, New York, United States
🇺🇸Aie001 50090, Winston-Salem, North Carolina, United States